Vimarsana
Biggest News Aggregation in the World

Page 7 - Regarding Forward Looking News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Regarding Forward Looking. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Regarding Forward Looking Today - Breaking & Trending Today

NewtekOne, Inc. Announces Loan Closings for the First Quarter 2024 - Vimarsana News

NewtekOne, Inc. Announces Loan Closings for the First Quarter 2024

Record Loan Approvals Across All Loan Products in First Quarter 2024 Strong Growth in Lending and Deposits in the First Quarter 2024 BOCA RATON, Fla., April 01, 2024 -- NewtekOne, Inc. ,...

NewtekOne, Inc. Promotes Frank M. DeMaria to Chief Accounting Officer - Vimarsana News

NewtekOne, Inc. Promotes Frank M. DeMaria to Chief Accounting Officer

BOCA RATON, Fla., April 01, 2024 -- NewtekOne, Inc. has promoted Mr. Frank M. DeMaria to Executive Vice President, Chief Accounting Officer of NewtekOne effective as of March 29, 2024. Mr....

CORRECTING and REPLACING NewtekOne, Inc. News Release - Vimarsana News

CORRECTING and REPLACING NewtekOne, Inc. News Release

BOCA RATON, Fla., April 01, 2024 -- Today NewtekOne, Inc. timely filed its annual report on Form 10-K for the period ended December 31, 2023. The purpose of this press release is to update and...

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results - Vimarsana News

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results

On track with plans to initiate Phase 2 trial for XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with microsatellite stable colorectal cancer in the...

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing - Vimarsana News

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and...